Bioalmanac
SS-31
Elamipretide · MTP-131 · Bendavia
A mitochondria-targeting peptide that reached phase 3 and missed its primary endpoints. The most rigorously tested compound on this site, and a cautionary tale about mechanism.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
Reconstitution — 50 mg vial, 10000 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 50 mg/mL | 0.2 mL | 20 units | 5 |
| 2 mL | 25 mg/mL | 0.4 mL | 40 units | 5 |
| 3 mL | 16.667 mg/mL | 0.6 mL | 60 units | 5 |
| 5 mL | 10 mg/mL | 1 mL | 100 units | 5 |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Phase 3 protocol | 40000 mcg | Once daily | Clinical trial |
| Commonly described community protocol | 5000–20000 mcg | Once daily | Community practice |
When to stop
- An injection site reaction that spreads, becomes hot, or produces pus. That is infection, not the expected irritation.
- Injection site nodules that persist between doses, leaving nowhere unaffected to inject.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Persistent headache or gastrointestinal upset that does not settle.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.